Ticaglide 90 is a prescription oral antiplatelet medication containing Ticagrelor 90 mg, specifically designed to reduce the risk of thrombotic cardiovascular events. It belongs to the class of P2Y12 platelet inhibitors, which work by preventing platelets in the blood from clumping together to form clots. This mechanism is crucial in individuals with a history of heart attack (myocardial infarction), acute coronary syndrome (ACS), or those who have undergone stent placement or coronary revascularization procedures.
Ticaglide 90 is often used in combination with low-dose aspirin as part of dual antiplatelet therapy (DAPT) to prevent serious complications such as stroke, heart attack, or cardiovascular-related death. Unlike older antiplatelet agents, Ticagrelor offers faster onset of action and reversible platelet inhibition, providing flexibility and potent protection against thrombotic events.
Its rapid and consistent antiplatelet activity helps maintain normal blood flow in patients with narrowed or blocked arteries, making it an essential therapy for long-term management of heart disease. The tablet is especially effective in high-risk cardiovascular patients who need aggressive secondary prevention strategies.
The benefits of Ticaglide 90 are most pronounced when used consistently and as prescribed, as skipping doses may compromise its effectiveness in preventing clots. Its use is generally preferred over clopidogrel in certain cases due to its superior clinical outcomes in major cardiovascular trials.
Patients taking Ticaglide 90 should be monitored for signs of bleeding, dyspnea (shortness of breath), and other side effects. It should not be used in patients with active bleeding disorders, severe liver impairment, or a history of intracranial hemorrhage. Routine follow-up and dose adjustments based on patient tolerance and response are key components of effective treatment.